LUNG · Pulmonx Corp · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-12-02 21:30 UTC | Piper Sandler 38th Annual Healthcare Conference | Conference |
Recent news
| Date | Headline |
|---|---|
| 2026-11-18 |
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38 th Annual Healthcare |
| 2026-11-17 |
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilation REDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in |
| 2026-10-28 |
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity |
| 2026-10-27 |
Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026. |
| 2026-10-13 |
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, |
| 2026-09-01 |
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 |
| 2026-08-27 |
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare |
| 2026-07-29 |
Pulmonx Reports Second Quarter 2026 Financial Results
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026. |
| 2026-07-28 |
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46 th Annual Growth |
| 2026-07-15 |
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, |
| 2026-06-01 |
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 |
| 2026-04-29 |
Pulmonx Reports First Quarter 2026 Financial Results
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. |
| 2026-04-28 |
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas |
| 2026-04-15 |
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, |
| 2026-03-04 |
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-11-11 | Stifel 2026 Healthcare Conference | Conference |
| 2026-11-11 | Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum | Event |
| 2026-10-27 | Pulmonx Q3 2026 Earnings Conference Call | Earnings call |
| 2026-08-11 | Canaccord Genuity 46th Annual Growth Conference | Conference |
| 2026-07-29 | Pulmonx Q2 2026 Earnings Conference Call | Earnings call |
| 2026-06-04 | Annual Meeting of Stockholders | Shareholder meeting |
| 2026-05-12 | Bank of America Securities 2026 Health Care Conference | Conference |
| 2026-04-29 | Pulmonx Q1 2026 Earnings Conference Call | Earnings call |
| 2026-03-04 | Pulmonx Q4 2025 Earnings Conference Call | Earnings call |
| 2025-11-12 | Pulmonx Q3 2025 Earnings Conference Call | Earnings call |
| 2025-09-11 | Lake Street Best Ideas Growth (BIG9) Conference | Conference |
| 2025-09-04 | Wells Fargo Healthcare Conference | Conference |
| 2025-08-12 | Canaccord Genuity 45th Annual Growth Conference | Conference |
| 2025-07-30 | Pulmonx Q2 2025 Earnings Conference Call | Earnings call |
Source: https://investors.pulmonx.com/